Residual tumor cells that drive disease relapse after chemotherapy do not have enhanced tumor initiating capacity.
about
Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer.Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid TumorsThe sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features.Emergent properties of a computational model of tumour growth.
P2860
Residual tumor cells that drive disease relapse after chemotherapy do not have enhanced tumor initiating capacity.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Residual tumor cells that driv ...... ced tumor initiating capacity.
@ast
Residual tumor cells that driv ...... ced tumor initiating capacity.
@en
Residual tumor cells that driv ...... ced tumor initiating capacity.
@nl
type
label
Residual tumor cells that driv ...... ced tumor initiating capacity.
@ast
Residual tumor cells that driv ...... ced tumor initiating capacity.
@en
Residual tumor cells that driv ...... ced tumor initiating capacity.
@nl
prefLabel
Residual tumor cells that driv ...... ced tumor initiating capacity.
@ast
Residual tumor cells that driv ...... ced tumor initiating capacity.
@en
Residual tumor cells that driv ...... ced tumor initiating capacity.
@nl
P2093
P2860
P1433
P1476
Residual tumor cells that driv ...... ced tumor initiating capacity.
@en
P2093
Cecile de la Cruz
E Alejandro Sweet-Cordero
Erica L Jackson
Ganapati V Hegde
Yanyan Zheng
P2860
P304
P356
10.1371/JOURNAL.PONE.0045647
P407
P577
2012-10-24T00:00:00Z